Circulating prostaglandin E2: a novel potential prognostic biomarker in patients with hepatocellular carcinoma

Clinical and Experimental Medicine - 2021
Filippo Pelizzaro1, Maria Piera Kitenge1, Romilda Cardin1, Alberto Ponzoni2, Umberto Cillo3, Alessandro Vitale3, Gianluca Businello4, Giada Munari4, Matteo Fassan4, Fabio Farinati1
1Gastroenterology Unit, Oncology and Gastroenterology, Department of Surgery, University of Padova, Padova, Italy
2Radiology Unit, Azienda-Ospedale Università Di Padova, Padova, Italy
3Hepatobiliary Surgery and Liver Transplantation Unit, Oncology and Gastroenterology, Department of Surgery, University of Padova, Padova, Italy
4Surgical Pathology and Cytopathology Unit, Department of Medicine, DIMED University of Padova, Padova, Italy

Tóm tắt

We aimed to explore the activation of monoacylglycerol lipase (MAGL)/cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) axis in hepatocellular carcinoma (HCC), evaluating circulating PGE2 as prognostic biomarker in HCC patients. PGE2 levels were measured in blood samples from 24 cirrhotics, and 34 HCC patients were consecutively collected between January 2016 and December 2017. In a subgroup of patients, tissue expression of MAGL mRNA and immunohistochemistry for MAGL and COX-2 were obtained. Despite tumor tissues showing overexpression of MAGL mRNA and higher levels of both MAGL and COX-2 at immunohistochemistry, PGE2 levels were not significantly different in HCC and cirrhotics. HCC patients with circulating PGE2 levels > 14 pg/mL had a significantly shorter overall survival (19.4 vs. 49.9 months; p = 0.03), the finding being confirmed by the multivariate analysis (HR 3.37 [95% CI 1.00–11.60]; p = 0.05). The MAGL/COX-2/PGE2 axis is activated in HCC, and circulating PGE2 proved to be a potential prognostic biomarker.

Từ khóa


Tài liệu tham khảo

Elsharkawy AM, Mann DA. Nuclear factor-κB and the hepatic inflammation-fibrosis-cancer axis. Hepatology. 2007;46:590–7.

Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev. 2006;32:28–44.

Habib A, Chokr D, Wan JH, et al. Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. Gut. 2019;68:522–32.

Zechner R, Zimmermann R, Eichmann TO, et al. FAT SIGNALS - Lipases and lipolysis in lipid metabolism and signaling. Cell Metab. 2012;15:279–91.

Tripathi RKP. A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents. Eur J Med Chem. 2020;188:111953.

Tardelli M. Monoacylglycerol lipase reprograms lipid precursors signaling in liver disease. World J Gastroenterol. 2020;26:3577–85.

Zang S, Ma X, Wu Y, et al. PGE2 synthesis and signaling in malignant transformation and progression of human hepatocellular carcinoma. Hum Pathol. 2017;63:120–7.

Cao Z, Mulvihill MM, Mukhopadhyay P, et al. Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology. 2013;144:808–17.

Tardelli M, Bruschi FV, Claudel T, et al. Lack of monoacylglycerol lipase prevents hepatic steatosis by favoring lipid storage in adipose tissue and intestinal malabsorption. J Lipid Res. 2019;60:1284–92.

Tardelli M, Bruschi FV, Fuchs CD, et al. Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis. Hepatology. 2020;71:1750–65.

Zhu W, Zhao Y, Zhou J, et al. Monoacylglycerol lipase promotes progression of hepatocellular carcinoma via NF-κB-mediated epithelial-mesenchymal transition. J Hematol Oncol. 2016;9:127.

Zhang J, Liu Z, Lian Z, et al. Monoacylglycerol lipase: a novel potential therapeutic target and prognostic indicator for hepatocellular carcinoma. Sci Rep. 2016;6:35784.

Lv X, Chen Z, Li S, Xie H. Knockdown of cyclooxygenase-2 leads to growth inhibition and cell cycle arrest in hepatocellular carcinoma cells. Onco Targets Ther. 2019;12:4341–9.

Tai Y, Zhang LH, Gao JH, et al. Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2. Cancer Manag Res. 2019;11:2831–48.

Chen G, Li X, Yang J, et al. Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis. Arch Med Sci. 2016;12:1110–7.

Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through akt activation: evidence for akt inhibition in celecoxib-induced apoptosis. Hepatology. 2003;38:756–68.

Li T, Zhong J, Dong X, et al. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway. Oncol Rep. 2016;35:3614–22.

Cheng SY, Zhang H, Zhang M, et al. Prostaglandin E2 receptor EP2 mediates snail expression in hepatocellular carcinoma cells. Oncol Rep. 2014;31:2099–106.

Xia S, Ma J, Bai X, et al. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway. Oncol Rep. 2014;32:1521–30.

Bai X, Wang J, Guo Y, et al. Prostaglandin E2 stimulates β1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-κB pathway. Sci Rep. 2014;4:6538.

Mayoral R, Fernández-Martínez A, Boscá L, Martín-Sanz P. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis. 2005;26:753–61.

Zhang H, Cheng S, Zhang M, et al. Prostaglandin E2 promotes hepatocellular carcinoma cell invasion through upregulation of YB-1 protein expression. Int J Oncol. 2014;44:769–80.

Qu L, Cai X, Xu J, et al. Six long noncoding RNAs as potentially biomarkers involved in competitive endogenous RNA of hepatocellular carcinoma. Clin Exp Med. 2020;20:437–47.

Weng J, Atyah M, Zhou C, Ren N. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma. Clin Exp Med. 2020;20:329–37.

Llovet JM, Ducreux M, Lencioni R, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.

Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63:1272–84.

Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. J Hepatol. 2013;58:956–61.

Chaud M, Faletti A, de Estrada MB, Gimeno AL, Gimeno MAF. Synthesis and release of prostaglandins D2 and E2 by rat uterine tissue throughout the sex cycle. Effects of 17-β-estradiol and progesterone. Prostaglandins, Leukot Essent Fat Acids. 1994;51:47–50.

Asselin E, Goff AK, Bergeron H, Fortier MA. Influence of sex steroids on the production of prostaglandins F2α and E2 and response to oxytocin in cultured epithelial and stromal cells of the bovine endometrium. Biol Reprod. 1996;54:371–9.

Neong SF, Billington EO, Congly SE. Sexual dysfunction and sex hormone abnormalities in patients with cirrhosis: review of pathogenesis and management. Hepatology. 2019;69:2683–95.

Thông tin
Thông tin xuất bản

Clinical and Experimental Medicine

Thông tin tác giả